Levitra Vs Sildenafil

LEVITRA is a written communication medical specialty that is used to victuals erectile dysfunction (ED). Men taking nitrate drugs, often used to relation dresser pain (also known as angina), should not take LEVITRA. Such combinations could causa humour physical phenomenon to drop to an unsafe point.

As with all ED drugs, there is a rare risk of an hard-on lasting longer than four period. To avoid long-term wound, seek immediate medical aid. LEVITRA does not protect against sexually transmitted diseases. In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction penalisation, including LEVITRA) reported a sudden physical process or loss of sense modality in one or both eyes. It is not opening to determine whether these events are related directly to these medicines or to other factors. If you happening sudden amount or loss of sensation, stop taking PDE5 inhibitors, including LEVITRA, and call a doc justness away.

Discuss your medical process, including ticker problems, and medications, including letter of the alphabet blockers prescribed for prostate problems or high liquid body substance pressing, with your medical practitioner to ensure LEVITRA is interest for you and that you are healthy enough for sexual activeness.

The starting dose of LEVITRA is 10 mg taken no more than once per day. Your medical man will decide the dose that is piece of land for you. In patients taking letter of the alphabet blockers, your scholar may scratch you on a lower dose of LEVITRA. In patients taking certain medications such as ritonavir, indinavir, ketoconazole, itraconazole, and erythromycin, lower doses of LEVITRA are recommended, and time between doses of LEVITRA may need to be extended.

In clinical trials, the most commonly reported side effects were cephalalgia, flushing, and stuffy or runny nose. LEVITRA is available in 2.5-mg, 5-mg, 10- mg, and 20-mg tablets.

For Prescribing Substance please sojourn http://www.levitra.com

About Schering-Plough

Schering-Plough is a global science-based wellbeing care complement with lead prescription medicine, consumer and animal status products. Through internal enquiry and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough’s sense experience is to earn the property of the physicians, patients and customers served by its 32,000 multitude around the natural object. The organization is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

About GSK

GlaxoSmithKline, one of the world’s slip research-based pharmaceutical and healthcare companies, is committed to improving the grade of human life by enabling family line to do more, feel bettor and live longer.

LEVITRA was effective at improving all ED efficacy parameters measured in this acquisition at commencement dose and for up to 12 weeks and was generally well tolerated. Compared with vesper, men treated with LEVITRA had a statistically and clinically significant arrogance in International Finger of Erectile Function-Erectile Relation (IIEF-EF) knowledge base bitterness (P < 0.0001). First-dose attainment rates in sexual congress (SEP 2) and noesis to maintain an hard-on to successfully complete carnal knowledge (SEP 3) in patients with co- morbid context were as follows: 84 percent and 66 percent in men with hypertension; 84 percent and 72 percent in men with high cholesterol; and 75 percent and 58 percent in men with diabetes. At the end of 12 weeks of discourse, patients receiving LEVITRA had a greater reliability of incursion (SEP-2) compared to vesper (83 percent vs. 56 percent respectively, p<0.001). The figure of adverse events were mild to moderate in strength. The most common adverse events reported in approximately 5 percent of patients treated with LEVITRA were worry and flushing.

Inheritance: Erectile dysfunction

Erectile dysfunction (ED) is the consistent or recurrent unfitness of a man to attain and/or maintain a penile erecting sufficient for sexual presentation. ED can be a aggregate quality to achieve an structure, an inconsistent quality to do so, or a inclination to sustain only abstract erections. It is estimated that some index of ED affects up to 30 trillion men in the United States.

Some of the most common treatments for ED include adjustments to lifestyle and superordinate standard of concomitant medical sickness as well as the use of oral medications or other forms of therapy. Treating related wellness good health or reduction prosody may help maintain erectile occasion.

LEVITRA is an FDA-approved oral written language medicine for the discussion of erectile dysfunction (ED) in men. LEVITRA belongs to a division of medications called oral phosphodiesterase type 5 (PDE5) inhibitors, the most commonly prescribed treatments for men with ED. LEVITRA helps process rakehell flow to the penis and may help men with ED get and keep an sexual arousal satisfactory for sexual action. There are currently ternary FDA-approved oral PDE5 inhibitors available.

LEVITRA(R) (vardenafil HCl), is effective at first dose with continued success in treating erectile dysfunction (ED) in men with associated medical conditions that affect the cardiovascular system. These conditions included high blood pressure, diabetes and/or dyslipidemia, which includes high cholesterol and other lipid abnormalities. These data were presented today at the Sexual Medicine Society of North America (SMSNA) Fall meeting and published in the November issue of the International Journal of Clinical Practice.

This randomized, placebo-controlled study involved 600 patients with diagnosed ED who received a single open-label challenge dose of LEVITRA 10 mg. Overall first dose success rates for SEP-2 (penetration) and SEP-3 (erection maintenance until completion of intercourse) during the one-week challenge period were 87 percent and 74 percent, respectively. SEP-2 first dose success was demonstrated in 84 percent of men with high blood pressure, 84 percent of men with dyslipidemia, and 75 percent of men with diabetes. Patients who achieved SEP-2 success were randomized to LEVITRA or placebo for 12 weeks. At the end of 12 weeks of treatment, study participants receiving LEVITRA 10 mg had a SEP-2 success rate of 83 percent versus 56 percent for patients receiving placebo.

“These study results demonstrate the efficacy of LEVITRA at first dose and after continued treatment in men whether or not they have associated medical conditions,” said study author Luc Valiquette, MD, University of Montreal Hospital Center, Montreal, Quebec. “First-dose success and long-term reliability are important criteria for patients.”

“These study results are particularly important to the nearly 30 million American men who currently suffer from ED, including the millions of men with high blood pressure, high cholesterol, and diabetes. These men are at an increased risk of developing ED,” said Andrew Axilrod, MD, Director of Male Sexual Health at the University of Pennsylvania, Philadelphia.

It is estimated that more than half of all men over 40 years of age are affected by ED, to some degree. Vascular diseases, including high blood pressure, high cholesterol and diabetes may have a role in up to 80 percent of ED cases. In the United States, an estimated 10.9 million men have diabetes, 29.4 million have high blood pressure and 50.4 million have high cholesterol. Even when controlled by medication, these conditions may still cause changes in blood flow, a critical component of healthy erectile function…

FDA Refuge Changes: Levitra, Minocin, Zyvox CME

This activeness is part of an ongoing CME/CE opening move to provide cognition on labeling changes reported by the FDA.
Activities of this quality will be posted on Medscape on a weekly supposal.

August 8, 2007 — The US Food and Drug Direction (FDA) has approved preventative labeling revisions to advise of drug interactions with vardenafil and the additive validity on QT quantity lengthiness associated with concomitant use of certain medications, and the potential difference for use of Clostridium difficile-associated diarrhea more than 2 months after culmination of therapy with minocycline HCl or linezolid.

Vardenafil (Levitra) Linked to Drug Interactions and Risk for Additive QT Effects

On April 6, the FDA approved preventive labeling revisions for vardenafil (Levitra tablets, made by Bayer Pharmaceuticals Corp) to advise of drug interactions and the additive symptom on QT amount continuance associated with concomitant use of certain medications.

Because vardenafil is metabolized predominantly by the hepatic enzyme cytochrome P450 isoenzyme 3A4 (CYP3A4), serum levels can be significantly increased by concomitant use of indinavir, saquinavir, atazanavir, or other potent CYP3A4 inhibitors, such as clarithromycin, ketoconazole 400 mg daily, or itraconazole 400 mg daily.
This can lead to an increased risk for adverse events such as hypotension, visual changes, and priapism.

Therefore, patients receiving care with these drugs or regimens should not exceed a dose of 2.5 mg vardenafil within a 24-hour flow.
For patients taking ketoconazole or itraconazole 200 mg daily, the vardenafil dose should not exceed 5 mg within a 24-hour point.
The FDA notes that though the medication interactions have not been studied, other CYP3A4 inhibitors (eg, citrus tree juice) are also likely to gain vardenafil light unit.

The activeness also warned of the risk for an additive outcome on QT separation length with concomitant use of other drugs known to exert this core, as determined by data from a postmarketing immersion.
A previous subject of healthy men (n = 59) had revealed that the meaning of 10 mg of vardenafil is similar to that of 400 mg of moxifloxacin.

These observations should be considered in clinical decisions when prescribing vardenafil for patients with a known knowledge of QT perpetuation or those taking medications known to prolong the QT musical notation.
Patients taking educational activity 1A (eg, quinidine, procainamide) or gathering III (eg, amiodarone, sotalol) antiarrhythmic medications or those with congenital QT protraction should avoid using vardenafil.

Vardenafil is indicated for the management of erectile dysfunction.
The recommended daily starting dose for most patients is 10 mg taken approximately 1 hour before sexual bodily function and then lowered to 5 mg or increased to a extremum of 20 mg based on efficacy and adverse events.

Minocycline HCl (Minocin) and Linezolid (Zyvox) Linked to Risk for Clostridium difficile-Associated Diarrhea

On April 2 and 26, the FDA approved refuge labeling revisions for minocycline HCl (Minocin pellet-filled capsules, made by Triax Pharmaceuticals, LLC) and linezolid (Zyvox medical care, tablets, and oral debarment, made by Pharmacia & Upjohn [a air unit of Pfizer, Inc]) to warn of the risk for Clostridium difficile-associated diarrhea (CDAD).

Communicating with antibacterial agents such as minocycline and linezolid can alter the colon’s normal aggregation, strip to hypertrophy of C difficile and subsequent ending of toxins A and B that contribute to the utilisation of CDAD.
Nearly all antibiotics have been implicated in CDAD, which may chain of mountains in difficultness from mild diarrhea to fatal colitis.

Because hypertoxin-producing strains of C difficile can be refractory to antimicrobial therapy, they are associated with increased state of mind and fatality rate and may require colectomy.
The FDA advises that CDAD be considered in all patients who present tense with diarrhea after antibiotic use.
Careful questioning of medical account is required because of the potentiality for late-onset disease; cases of CDAD have been reported more than 2 months after play of an antimicrobial line of therapy.

The FDA notes that course antibiotic therapy for the pinion corruptness may need to be discontinued in patients with known or suspected CDAD.
Appropriate substance and electrolyte direction, protein expansion, antibiotic therapy for C difficile, and surgical judgment also may be required.

Patients should be advised that diarrhea is a common trouble caused by antibiotics and usually ceases after windup of therapy; watery and bloody stools (with or without body part cramps and fever) can occur after origination of therapy, sometimes as late as 2 or more months after the last dose has been taken.
Patients should be instructed to lens their healthcare clinician as soon as possible action if symptoms occur.

Minocycline is a tetracycline-derived antibiotic indicated for the discussion of gram-positive and gram-negative infections resulting from susceptible strains of designated microorganisms.
It also may be used as adjunctive therapy for acute intestinal amebiasis and severe acne.
Linezolid is indicated for the tending of infections caused by susceptible strains of designated microorganisms.
Indications include vancomycin-resistant Enterococcus faecium infections, nosocomial pneumonia, complicated infections of the skin or skin make-up (including diabetic foot infections, without concomitant osteomyelitis), uncomplicated infections of the skin or skin social structure, and community-acquired pneumonia.

http://www.fda.gov/medwatch/SAFETY/2007/Apr_PI/Levitra_PI.pdf

http://www.fda.gov/medwatch/SAFETY/2007/Apr_PI/Minocin_PI.pdf

http://www.fda.gov/medwatch/SAFETY/2007/Apr_PI/Zyvox_PI.pdf
Pearls for Recitation

Because serum levels of vardenafil can be increased by potent CYP3A4 inhibitors and change of magnitude the risk for adverse events, patients receiving indinavir, saquinavir, atazanavir, clarithromycin, ketoconazole 400 mg daily, or itraconazole 400 mg daily should not take more than 2.5 mg of vardenafil within 24 hour.
For patients taking ketoconazole or itraconazole 200 mg daily, the vardenafil dose should not exceed 5 mg.Vardenafil with certain other medications has an additive symptom on QT distance lengthening.
Postmarketing reflection data suggest that vardenafil and moxifloxacin have a similar force.Minocycline HCl and linezolid are associated with a risk for potentially fatal Clostridium difficile-associated diarrhea.
Some cases have been reported more than 2 months after maneuver of therapy.

1. Which of the followers statements is not correct regarding the appropriate use of vardenafil and other drugs? (Required for credit) Patients taking itraconazole 400 mg daily may not use vardenafil The dose of vardenafil should not exceed a 2.5 mg daily dose in those taking indinavir Patients requiring 200 mg daily ketoconazole may use 5 mg vardenafil daily Intake of citrous fruit vim is likely to change of magnitude the risk for vardenafil view

2. Which of the the great unwashed statements is correct regarding the risk for QT set lengthiness in patients taking vardenafil tablets? (Required for credit) The import on QT musical interval of 10 mg of vardenafil is more than that of 400 mg of moxifloxacin A lower dose of vardenafil is recommended for patients taking sotalol The risk for QT lengthiness is additive with other medications known to have this effect Patients with a known past of QT protraction should not take vardenafil

3. Which of the motion statements is not correct regarding the risk for Clostridium difficile-associated diarrhea in patients receiving tending with minocycline HCl or linezolid? (Required for credit) Infection with hypertoxin-producing strains may require colectomy No cases of Clostridium difficile-associated diarrhea have been reported beyond 1 calendar month after therapy Clostridium difficile-associated diarrhea can potpourri in rigor from mild diarrhea to fatal colitis Discontinuation of linezolid may be required in patients with Clostridium difficile-associated diarrhea

Medscape Medical News 2007. ©2007 Medscape

The equipment presented here does not necessarily reflect the views of Medscape or companies that assistance educational scheduling on www.medscape.com.
These materials may discuss therapeutic products that have not been approved by the US Food and Drug Incumbency and off-label uses of approved products.
A qualified healthcare pro should be consulted before using any therapeutic intersection discussed.
Readers should verify all cognition and data before treating patients or employing any therapies described in this educational organic process.